MedPath

Characterization of White Blood Cells Sub-populations From Multiple Sclerosis Patients.

Conditions
Multiple Sclerosis
Interventions
Other: Blood Sampling
Other: CSF Sampling
Registration Number
NCT03486665
Lead Sponsor
Bioimmunate
Brief Summary

Multiple sclerosis (MS) is a chronic progressive neurological autoimmune disease, that gradually affects patient's quality of life. There are about 2.5 millions patients world wide, with an increasing cost Burdon. Up to date, it remains unclear who are the exact cells to initiate the disease. During the disease, the repertoire of cells expands and undergoes changes. The purpose of this study is to characterize those changes.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Patients with diagnosis of MS according to the revised criteria of McDonald or healthy volunteers
  • Ability to provide written informed consent.
Exclusion Criteria
  • Active malignant disease

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Diagnosed with Multiple SclerosisBlood SamplingPatients previously diagnosed with Multiple Sclerosis
Healthy VolunteersBlood SamplingHealth volunteers who do not have an autoimmune diseases, including Multiple Sclerosis
Newly Diagnosed with Multiple SclerosisBlood SamplingPatients diagnosed for the first time with Multiple Sclerosis and hospitalized
Newly Diagnosed with Multiple SclerosisCSF SamplingPatients diagnosed for the first time with Multiple Sclerosis and hospitalized
Primary Outcome Measures
NameTimeMethod
Quantification of disease related white blood cells from blood and/ or CSFthrough study completion, an average of 6 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Hadassah Medical Center

🇮🇱

Jerusalem, Israel

© Copyright 2025. All Rights Reserved by MedPath